Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184

by Paul Quintaro, Benzinga Editor
January 9, 2013 11:38 AM | 8 seconds read |
Idenix IDIX comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!